Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michel Weiwer is active.

Publication


Featured researches published by Michel Weiwer.


Journal of Biological Chemistry | 2010

Chemoenzymatic Design of Heparan Sulfate Oligosaccharides

Renpeng Liu; Yongmei Xu; Miao Chen; Michel Weiwer; Xianxuan Zhou; Arlene S. Bridges; Paul L. DeAngelis; Qisheng Zhang; Robert J. Linhardt; Jian Liu

Heparan sulfate is a sulfated glycan that exhibits essential physiological functions. Interrogation of the specificity of heparan sulfate-mediated activities demands a library of structurally defined oligosaccharides. Chemical synthesis of large heparan sulfate oligosaccharides remains challenging. We report the synthesis of oligosaccharides with different sulfation patterns and sizes from a disaccharide building block using glycosyltransferases, heparan sulfate C5-epimerase, and sulfotransferases. This method offers a generic approach to prepare heparan sulfate oligosaccharides possessing predictable structures.


Journal of Medicinal Chemistry | 2013

Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.

Florence F. Wagner; David E. Olson; Jennifer Gale; Taner Kaya; Michel Weiwer; Nadia Aidoud; Meryl Thomas; Emeline L. Davoine; Bérénice C. Lemercier; Yan-Ling Zhang; Edward B. Holson

Hydroxamic acids were designed, synthesized, and evaluated for their ability to selectively inhibit human histone deacetylase 6 (HDAC6). Several inhibitors, including compound 14 (BRD9757), exhibited excellent potency and selectivity despite the absence of a surface-binding motif. The binding of these highly efficient ligands for HDAC6 is rationalized via structure-activity relationships. These results demonstrate that high selectivity and potent inhibition of HDAC6 can be achieved through careful choice of linker element only.


Journal of Medicinal Chemistry | 2008

Oversulfated Chondroitin Sulfate: Impact of a Heparin Impurity, Associated with Adverse Clinical Events, on Low-Molecular-Weight Heparin Preparation

Zhenqing Zhang; Michel Weiwer; Boyangzi Li; Melissa M. Kemp; Tyler H. Daman; Robert J. Linhardt

Heparin, a widely used anticoagulant, is being rapidly displaced by low-molecular-weight heparins. Recently, certain lots of heparin have been associated with anaphylactoid-type reactions resulting from contamination with oversulfated chondroitin sulfate. This impurity has also contaminated low-molecular-weight heparins obtained by chemical and enzymatic depolymerization of heparin. The sensitivity of oversulfated chondroitin sulfate to five different depolymerization processes similar to ones used in preparing low-molecular-weight heparins is reported.


Journal of Medicinal Chemistry | 2013

Discovery of the First Histone Deacetylase 6/8 Dual Inhibitors

David E. Olson; Florence F. Wagner; Taner Kaya; Jennifer Gale; Nadia Aidoud; Emeline L. Davoine; Fanny Lazzaro; Michel Weiwer; Yan-Ling Zhang; Edward B. Holson

We disclose the first small molecule histone deacetylase (HDAC) inhibitor (3, BRD73954) capable of potently and selectively inhibiting both HDAC6 and HDAC8 despite the fact that these isoforms belong to distinct phylogenetic classes within the HDAC family of enzymes. Our data demonstrate that meta substituents of phenyl hydroxamic acids are readily accommodated upon binding to HDAC6 and, furthermore, are necessary for the potent inhibition of HDAC8.


ACS Medicinal Chemistry Letters | 2012

Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria

Richard Heidebrecht; Carol Mulrooney; Christopher P. Austin; Robert Barker; Jennifer A. Beaudoin; Ken Chih-Chien Cheng; Eamon Comer; Sivaraman Dandapani; Justin Dick; Jeremy R. Duvall; Eric Ekland; David A. Fidock; Mark E. Fitzgerald; Michael A. Foley; Rajarshi Guha; Paul L. Hinkson; Martin Kramer; Amanda K Lukens; Daniela Masi; Lisa A. Marcaurelle; Xin-Zhuan Su; Craig J. Thomas; Michel Weiwer; Roger Wiegand; Dyann F. Wirth; Menghang Xia; Jing Yuan; Jinghua Zhao; Michelle Palmer; Benito Munoz

Here, we describe the discovery of a novel antimalarial agent using phenotypic screening of Plasmodium falciparum asexual blood-stage parasites. Screening a novel compound collection created using diversity-oriented synthesis (DOS) led to the initial hit. Structure–activity relationships guided the synthesis of compounds having improved potency and water solubility, yielding a subnanomolar inhibitor of parasite asexual blood-stage growth. Optimized compound 27 has an excellent off-target activity profile in erythrocyte lysis and HepG2 assays and is stable in human plasma. This compound is available via the molecular libraries probe production centers network (MLPCN) and is designated ML238.


Current Vascular Pharmacology | 2008

The Role of the Methoxyphenol Apocynin, a Vascular NADPH Oxidase Inhibitor, as a Chemopreventative Agent in the Potential Treatment of Cardiovascular Diseases

Jingjing Yu; Michel Weiwer; Robert J. Linhardt; Jonathan S. Dordick

Oxidative stress has been linked to the origin and progression of cardiovascular diseases. Nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase is a multi-component, NADPH-dependent enzyme that generates superoxide anion in the presence of molecular oxygen. The enzyme has been identified and characterized in all 3 vascular wall cell types and represents the major source of reactive oxygen species (ROS) production in the vascular wall. Inhibition of NADPH oxidase activation appears to suppress the sequence of cellular events that leads to a variety of cardiovascular diseases, including atherosclerosis. The naturally occurring methoxyphenol apocynin has been found to inhibit NADPH oxidase upon activation by peroxidases (e.g. soybean peroxidase, myeloperoxidase) or ROS under mild reaction conditions. Upon peroxidase-catalyzed activation, the apocynin oxidation products act to block the assembly and activation of NADPH oxidase. Although the mechanism of inhibition of NADPH oxidase remains largely unknown, apocynins high effectiveness and low toxicity makes it a promising lead compound in the development of new therapeutic agents for cardiovascular diseases.


Bioorganic & Medicinal Chemistry Letters | 2012

Development of small-molecule probes that selectively kill cells induced to express mutant RAS

Michel Weiwer; Joshua Bittker; Tim Lewis; Kenichi Shimada; Wan Seok Yang; Lawrence MacPherson; Sivaraman Dandapani; Michelle Palmer; Brent R. Stockwell; Stuart L. Schreiber; Benito Munoz

Synthetic lethal screening is a chemical biology approach to identify small molecules that selectively kill oncogene-expressing cell lines with the goal of identifying pathways that provide specific targets against cancer cells. We performed a high-throughput screen of 303,282 compounds from the National Institutes of Health-Molecular Libraries Small Molecule Repository (NIH-MLSMR) against immortalized BJ fibroblasts expressing HRAS(G12V) followed by a counterscreen of lethal compounds in a series of isogenic cells lacking the HRAS(G12V) oncogene. This effort led to the identification of two novel molecular probes (PubChem CID 3689413, ML162 and CID 49766530, ML210) with nanomolar potencies and 4-23-fold selectivities, which can potentially be used for identifying oncogene-specific pathways and targets in cancer cells.


Journal of Organic Chemistry | 2012

Chemoenzymatic synthesis of uridine diphosphate-GlcNAc and uridine diphosphate-GalNAc analogs for the preparation of unnatural glycosaminoglycans.

Sayaka Masuko; Smritilekha Bera; Dixy E. Green; Michel Weiwer; Jian Liu; Paul L. DeAngelis; Robert J. Linhardt

Eight N-acetylglucosamine-1-phosphate and N-acetylgalactosamine-1-phosphate analogs have been synthesized chemically and were tested for their recognition by the GlmU uridyltransferase enzyme. Among these, only substrates that have an amide linkage to the C-2 nitrogen were transferred by GlmU to afford their corresponding uridine diphosphate(UDP)-sugar nucleotides. Resin-immobilized GlmU showed comparable activity to nonimmobilized GlmU and provides a more facile final step in the synthesis of an unnatural UDP-donor. The synthesized unnatural UDP-donors were tested for their activity as substrates for glycosyltransferases in the preparation of unnatural glycosaminoglycans in vitro. A subset of these analogs was useful as donors, increasing the synthetic repertoire for these medically important polysaccharides.


Bioorganic & Medicinal Chemistry | 2012

Unbiased binding assays for discovering small-molecule probes and drugs

Melissa M. Kemp; Michel Weiwer; Angela N. Koehler

2011 marks the 10-year anniversary of milestone manuscripts describing drafts of the human genome sequence. Over the past decade, a number of new proteins have been linked to disease-many of which fall into classes that have been historically considered challenging from the perspective of drug discovery. Several of these newly associated proteins lack structural information or strong annotation with regard to function, making development of conventional in vitro functional assays difficult. A recent resurgence in the popularity of simple small molecule binding assays has led to new approaches that do not require knowledge of protein structure or function in advance. Here we briefly review selected methods for executing binding assays that have been used successfully to discover small-molecule probes or drug candidates.


Bioorganic & Medicinal Chemistry | 2009

Inhibition of human vascular NADPH oxidase by apocynin derived oligophenols

Mauricio Mora-Pale; Michel Weiwer; Jingjing Yu; Robert J. Linhardt; Jonathan S. Dordick

Enzymatic oxidation of apocynin, which may mimic in vivo metabolism, affords a large number of oligomers (apocynin oxidation products, AOP) that inhibit vascular NADPH oxidase. In vitro studies of NADPH oxidase activity were performed to identify active inhibitors, resulting in a trimer hydroxylated quinone (IIIHyQ) that inhibited NADPH oxidase with an IC(50)=31nM. Apocynin itself possessed minimal inhibitory activity. NADPH oxidase is believed to be inhibited through prevention of the interaction between two NADPH oxidase subunits, p47(phox) and p22(phox). To that end, while apocynin was unable to block the interaction of his-tagged p47(phox) with a surface immobilized biotinylated p22(phox) peptide, the IIIHyQ product strongly interfered with this interaction (apparent IC(50)=1.6microM). These results provide evidence that peroxidase-generated AOP, which consist of oligomeric phenols and quinones, inhibit critical interactions that are involved in the assembly and activation of human vascular NADPH oxidase.

Collaboration


Dive into the Michel Weiwer's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stuart L Schreiber

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christopher P. Austin

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Craig J. Thomas

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge